AHIP: Price gouging gets worse for out-of-network COVID-19 tests

A test tube with a blood sample
A new America’s Health Insurance Plans survey found that price-gouging on out-of-network COVID-19 tests has gotten worse. (Getty Images/photoguns)

New data from an insurance industry group find price gouging for out-of-network COVID-19 tests has increased since a July survey, and insurers want Congress to step in.

The data (PDF), released Monday from America’s Health Insurance Plans (AHIP), comes as most providers agreed to offer COVID-19 testing and treatments without cost-sharing. 

AHIP conducted a survey of 22 of its members, representing 76% of commercial enrollment of AHIP member plans.

Report

Driving Engagement in an Evolving Healthcare Ecosystem

Deep-dive into evolving consumer expectations in healthcare today and how leading providers are shaping their infrastructure to connect with patients through virtual care.

On average, a COVID-19 test in the commercial market costs $130, and out-of-network tests cost more than $185.

“Between 9% and 16% of out-of-network test claims charged more than $390 (three times the average cost),” AHIP’s report said.

RELATED: HHS calls on FDA to speed up reviews of lab-developed COVID-19 tests after backlog

It found that nearly a quarter of COVID-19 tests are administered out of network, which is a 14% increase from a similar survey of 22 members taken in July.

AHIP found that the out-of-network costs were also going up.

“The share of claims for diagnostic and antibody tests for COVID-19 that cost more than 50% of the average cost ($185) increased by almost 10%,” the group said.

The survey also said that most of the high-priced tests came from standalone labs (58%), 18% came from hospital outpatient clinics and 18% at a doctor’s office.

AHIP said that the CARES Act requires insurers to pay the listed cash price for a COVID-19 test if there isn’t a contract with the provider or lab, “thus eliminating their ability to negotiate more affordable test prices.”

The group urged lawmakers to create a “reasonable market-based pricing benchmark” for any out-of-network tests.

Suggested Articles

Despite efforts to improve patient safety over the past 20 years, results have not been optimal. We raise vital questions and renewed areas of focus.

The Trump administration has enlisted CVS Health to pilot administering the therapy to patients in long-term care facilities and at home.

It's been a big week for health tech startup Olive.